Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March
09 févr. 2021 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021
08 févr. 2021 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis
14 janv. 2021 07h00 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of...
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
13 janv. 2021 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
11 janv. 2021 09h01 HE
|
Organogenesis Holdings Inc.
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis RMAT Designation Enables Closer...
Organogenesis Holdings Inc. to Participate in the ICR Conference 2021
05 janv. 2021 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock
13 nov. 2020 00h45 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock
10 nov. 2020 17h40 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
09 nov. 2020 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Latest Wound Care Research from Organogenesis Highlighted at SAWC Fall 2020 Virtual Meeting
02 nov. 2020 16h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of...